ImmPACT Bio
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their treatment options. The company’s logic-gate-based CAR T-cell platforms, licensed from UCLA Technology Development Group (TDG), address key biological challenges in treating cancer. ImmPACT Bio’s technologies are specifically designed to prevent antigen escape, and to overcome the immunosuppressive tumor microenvironment. The company’s technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from University of California, Los Angeles (UCLA).
